SLC45A3 and neoplasm: In particular, Hernández‐Llodrà et al. found that a combination of ERG overexpression with PTEN and SLC45A3 (prostein) expression loss (a phenotype called “triple hit”) is associated with tumor progression and may represent another option to improve the risk category assignment [17].